MBM (drug)

MBM
Clinical data
Other names4-Butoxy-2,5-dimethoxyamphetamine; 2,5-Dimethoxy-4-butoxyamphetamine; TMA2-4-BuO
Routes of
administration		Oral[1][2][3]
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist
ATC code
  • None
Pharmacokinetic data
Duration of actionUnknown[1][2][3]
Identifiers
  • 1-(4-butoxy-2,5-dimethoxyphenyl)propan-2-amine
PubChem CID
ChemSpider
Chemical and physical data
FormulaC15H25NO3
Molar mass267.369 g·mol−1
3D model (JSmol)
  • CCCCOC1=C(C=C(C(=C1)OC)CC(C)N)OC
  • InChI=1S/C15H25NO3/c1-5-6-7-19-15-10-13(17-3)12(8-11(2)16)9-14(15)18-4/h9-11H,5-8,16H2,1-4H3
  • Key:QKAUNHGCSPPQBX-UHFFFAOYSA-N

MBM, also known as 2,5-dimethoxy-4-butoxyamphetamine or as TMA2-4-BuO, is a serotonin receptor modulator of the phenethylamine, amphetamine, and DOx families.[1][2][3] It is a derivative of the DOx psychedelics TMA-2 and MEM in which the 4-position substituent has been extended.[1][2][3] According to Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved), MBM produced no effects at doses of up to 12 mg orally.[1][2][3][4] Higher doses were not tested.[1][2][3] As such, the properties and effects of MBM remain unknown.[1][2][3] The drug is a potent full agonist of the serotonin 5-HT2A and 5-HT2C receptors (EC50Tooltip half-maximal effective concentration (EmaxTooltip maximal efficacy) = 26.9 nM (114%) and 57.4 nM (93%), respectively).[5] Conversely, it is inactive as an agonist of the serotonin 5-HT2B and 5-HT1A receptors.[5] The chemical synthesis of MBM has been described.[1][5] MBM was first described in the literature by Shulgin in PiHKAL in 1991.[1][2]

See also

References

  1. 1 2 3 4 5 6 7 8 9 Shulgin A, Shulgin A (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628. "The extension of the 4-alkoxy-group led to the discovery of the TMA-2—MEM—MIPM—MPM—MBM series of amphetamine analogues. The 2-carbon counterparts of these would be a fascinating series to explore, I thought, if there was some encouragement to be had from a preliminary try in this field." [...] "These are the exact analogues of 2C-T-2, 2C-T-7, and 2C-T-19, resp., and the 2-carbon homologues of MEM, MPM, and MBM." [...] "Three additional materials of this pattern were prepared and either shown to be even less active, or simply were not assayed at all. These are the 4-isopropoxy isomer (MIPM), the n-butoxy homologue (MBM), and the n-amyl homologue (MAM). They scarcely warrant separate recipes as they were all made in a manner similar to this one describing MPM." [...] "For the preparation of MBM, the starting phenol was alkylated to 2-n-butoxy-1,4-dimethoxybenzene in methanolic KOH with n-butyl bromide. The benzaldehyde melted at 79.5–81 °C from methanol, and formed a malononitrile derivative that had a melting point of 134.5–135 °C. The nitrostyrene from the aldehyde and nitroethane in acetic acid crystallized from methanol with a mp of 71–72 °C. Lithium aluminum hydride reduction in ether gave the ether-insoluble chloroform-soluble product 4-n-butoxy-2,5-dimethoxyamphetamine hydrochloride (MBM) with a melting point of 128–130 °C. This product met all tests for structural integrity, and assays were started. At levels of up to 12.0 milligrams, there were no effects noted."
  2. 1 2 3 4 5 6 7 8 Shulgin A, Manning T, Daley PF (2011). The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds. Vol. 1. Berkeley: Transform Press. ISBN 978-0-9630096-3-0.
  3. 1 2 3 4 5 6 7 Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine: von der Struktur zur Funktion [Phenethylamines: From Structure to Function]. Nachtschatten-Science (in German) (1 ed.). Solothurn: Nachtschatten-Verlag. ISBN 978-3-03788-700-4. OCLC 858805226. Archived from the original on 21 August 2025.
  4. ↑ Kolaczynska KE, Luethi D, Trachsel D, Hoener MC, Liechti ME (2019). "Receptor Interaction Profiles of 4-Alkoxy-Substituted 2,5-Dimethoxyphenethylamines and Related Amphetamines". Frontiers in Pharmacology. 10 1423. doi:10.3389/fphar.2019.01423. PMC 6893898. PMID 31849671. Although the 2C-O derivatives initially examined by Shulgin were shown to be fairly inactive in humans (2C-O-1; 21 and 2C-O-4; 22, Figure 3) some derivatives such as 19 and 2,5-dimethoxy-4-ethoxyamphetamie (MEM) (24) displayed psychedelic activity (Figure 3) (Shulgin and Shulgin, 1991). However, upon further increasing chain length to a 4-propyloxy (MPM; 26) or 4-butyloxy (MBM; structure not shown) substituent, again no psychoactive effects could be observed on comparable doses as used for 19 and 24. The rather mixed results of low human potency and inactivity was one of the reasons Shulgin did not further evaluate the structure-activity relationship (SAR) of the 2C-O and 3C-O derivatives.
  5. 1 2 3 WO 2022192781A1, Kruegel AC, "Phenalkylamines and methods of making and using the same", published 15 September 2022, assigned to Gilgamesh Pharmaceuticals Inc.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.